Table 1. Randomized controlled trials focus on intraperitoneal chemotherapy for primary EOC and recurrent EOC.
| First authors (ref.) | Year | Type of study | Primitive/Recurrence | FIGO stage | IP therapy technique | no. of pts | Chemotherapy regimen | Pl-Sensitive pts | CC0-1 n (%) | OS (months) [5y-OS%] | DFS or PFS (months) | Morbidity (3-4 grade/severe) % | Mortality % |
| Koole (15) | 2019 | RCT | pEOC | III | HIPEC | 122 | NACT (3 cycles carbo + taxol) + I-CRS+HIPEC (Cis 100 mg/m2) + ACT (3 cycles carbo + taxol) | – | R1: 82 (67), R2a: 24 (20), R2b: 14 (11) | No significant differences in health-related QoL outcomes | |||
| 123 | NACT (3 cycles carbo + taxol) + I-CRS alone + ACT (3 cycles carbo + taxol) | – | R1: 84 (69), R2a: 22 (18), R2b: 13 (11) | ||||||||||
| Van Driel (16) | 2018 | RCT | pEOC | III | HIPEC | 118 | NACT (3 cycles carbo + taxol) + I-CRS+HIPEC (Cis 100 mg/m2) + ACT (3 cycles carbo + taxol) | – | R1: 84 (69), R2a: 22 (18), R2b: 13 (11) | mOS 45.7 | RFS 14.2 | 32 (27) | 0 (0) |
| 122 | NACT (3 cycles carbo + taxol) + I-CRS alone + ACT (3 cycles carbo + taxol) | – | R1: 82 (67), R2a: 24 (20), R2b: 14 (11) | mOS 33.9 (P=0.02) | RFS 10.7 (P=0.02) | 30 (25) (P=NS) | 1 (0.8) | ||||||
| Lim (17) | 2017 | RCT | pEOC | III−IVV | HIPEC | 92 | U-CRS+HIPEC (Cis 75 mg/m2) | – | – | NR [49.4%] | [5y-PFS 16%] | NA (67.4) anemia, NA (15.2) increase creatinine | 0 (0) |
| 92 | U-CRS alone | – | – | NR [51%] (P=NS) | [5y-PFS 20.9%] (P=NS) | NA (50) anemia, NA (4.3) increase creatinine (P=0.025 and 0.026) | 0 (0) | ||||||
| Spiliotis (18) | 2015 | RCT | rEOC | IIIC-IV | HIPEC | 60 | CRS+HIPEC (Cis 100 mg/m2+Paclitaxel 175 mg/m2 for platinum-S) or (Doxo 35 mg/m2 + Paclitaxel 175 mg/m2 or MMC 15 mg/m2 for platinum-R) | Pl-S: 38 (63.3), Pl-R: 22 (36.7) | CC-0: 39 (65), CC-1: 12 (20), CC-2: 9 (15) | mOS 26.7 Stage IIIC: 26.9, Stage IV: 26.4; Pl-S: 26.8, Pl-R: 26.6; CC-0: 30.9, CC-1: 23.9, CC-2: 12.1 | – | – | – |
| 60 | CRS + post-op IV CT | Pl-S: 36 (60), Pl-R: 24 (40) | CC-0: 33 (55), CC-1: 20 (33.3), CC-2: 7 (11.7) | mOS: 13.4 (p<0.006); Stage IIIC: 14.2; Stage IV: 11.9; Pl-S: 15.2, Pl-R: 10.2; CC-0: 16.1, CC-1: 11, CC-2: 6.7 | – | – | – | ||||||
Pl-R, platinum-resistant; Pl-S, platinum-sensitive; Cis, Cisplatin; Doxo, Doxorubicin; MMC, Mitomycin C; Oxa, Oxaliplatin; Carbo, Carboplatin; mOS, median overall survival; rEOC, recurrent EOC; pEOC, primary EOC; NR, not reported; NA, not available; IV, intravenous; CT, chemotherapy; NACT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy; U-, upfront; I-, interval; NS, not significant; PF, progression-free survival; RFS, recurrence-free survival; DFS, disease-free survival.